GNLX

#3931
Genelux Corporation Common Stock
2.62 USD
+3.56%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
2.60
2.62
Year Range
2.25
8.54
Daily Change
+3.56%
Monthly Change
-0.76%
6 month change
-50.38%
Year Change
+4.38%
Previous Close
2.53
Open
2.62
Bid
Ask
Low
2.60
High
2.62
Volume
18
Open full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 117.39 M
  • Employee 26
  • Founded 2001
  • CEO N/A
  • Website www.genelux.com
  • Headquarter Delaware, United States
  • FIGI BBG0044BNBX6
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-5.07
Price to sales ratio
20.26 K

Genelux Corporation

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME.

News